Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study
Authors' conclusion
Decision support tool for self-managed insulin dosing in individuals with T1D using MDI was feasible, safe, and improved glycemic control, supporting further evaluation in large-scale randomized trials.
Study context
- Population
- Young adults with T1D managed with MDI and continuous glucose monitoring (CGM); mean age 25.1 ± 4.1 years, 56% female, mean HbA1c 7.6% ± 0.8%completed the study
- Participants
- 16 adults
- Exposure
- End of intervention vs baseline with AI-DSS
- Outcome
- Primary safety outcomes: percent time <54 mg/dL and >250 mg/dL
- Follow-up
- Last 2 weeks of intervention vs last 2 weeks of run-in
Methodological details4-week run-in, 12-week intervention
- 4-week run-in
- 12-week intervention
Main finding
As reported in the abstract
- Time <54 mg/dL remained unchanged
- Trend toward reduced time >250 mg/dL
- Intervention vs Baseline: P = 0.191
- Intervention vs Baseline: P = 0.055
Observational data: associations, not effects.
Secondary outcomes
Median HbA1c · start to end of study · significantly decreased
P = 0.013
Time in range (TIR) (70-180 mg/dL)
- TIR significantly improved by (P = 0.039)
- 3.5% ± 7.3%
Safety
- Severe adverse events reported
- 0
Original publication
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study. Diabetes Technol Ther. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →